Skip to main content
. 2021 Dec 5;57:103458. doi: 10.1016/j.msard.2021.103458

Fig. 1.

Fig 1

Monthly incidence rate of SARS-CoV-2 infection among multiple sclerosis (MS) patients receiving disease-modifying therapies (DMTs) versus the general population of 20-years-old or above in England. Data for individual DMTs are presented in separate graphs. The coloured line in each graph is the incidence rate of infection during each month per 100 MS patients taking each DMT, and the shaded areas are the 95% confidence intervals. The black line is the incidence rate of infection during each month per 100 people aged 20 years or above in the general population. The dashed gray line is the cumulative SARS-CoV-2 vaccination (both doses) uptake during each month among the adult population in England.